Intensive Blood Pressure Targets Fell Short of Lowering Cardiovascular Events in Type 2 Diabetes
Intensive treatment to push systolic blood pressure below 120 mm Hg did not significantly reduce major cardiovascular events in adults with Type 2 diabetes enrolled in the OPTIMAL-DIABETES trial. The comparison was straightforward: a lower target against a more conventional one, with cardiovascular death, stroke, heart attack, heart failure hospitalization, and unstable angina folded into the primary outcome. After a median follow-up of four years, the event curves ran close enough together that the difference did not reach statistical significance.
The finding matters because blood pressure control sits near the center of cardiovascular prevention in diabetes, where vascular injury, arterial stiffness, endothelial dysfunction, and accelerated atherosclerosis converge. Yet diabetes also brings a tighter safety tradeoff than hypertension alone. Kidney perfusion, medication burden, and the risk of overcorrection all become part of the treatment equation when clinicians try to drive pressure substantially lower.
One sentence captures the central result: a lower number on the cuff did not translate into a clearly lower rate of major cardiovascular events.
The trial enrolled 9,476 adults at 33 sites in Brazil, all at least 50 years old and all with systolic blood pressure between 130 and 180 mm Hg. The average age was 65, and 62% of participants were women. Baseline risk was substantial: 28.5% had established cardiovascular disease, 3.9% had subclinical cardiovascular disease, and 22.6% had chronic kidney disease. Others entered the study with risk factors such as smoking, high cholesterol, or age 75 years or older. This was not a low-risk population; the biology of vascular injury was already well advanced at enrollment.
Participants were assigned to either intensive treatment aimed at systolic pressure below 120 mm Hg or standard treatment targeting below 140 mm Hg. During follow-up, blood pressure medication was adjusted to meet those goals. Average systolic pressure, excluding the first three months, settled at 122 mm Hg in the intensive arm and 135 mm Hg in the standard arm. The separation in blood pressure was real, sustained, and clinically meaningful. It was still not enough to produce a statistically significant difference in the primary cardiovascular endpoint.
The intensive group had 286 major cardiovascular events, or 6.0%, versus 315 events, or 6.7%, in the standard group. That works out to roughly a 10% relative reduction, but not one that crossed the threshold for statistical significance. For clinicians, that is a familiar and frustrating pattern: a signal that may be clinically suggestive, but not definitive enough to justify a universal shift in target for every patient with diabetes.
Kidney outcomes moved in the opposite direction. Kidney-related events occurred in 270 participants, or 5.7%, in the intensive group compared with 175 participants, or 3.7%, in the standard group. Most of these were declines in kidney function, while only a small number progressed to end-stage renal disease. End-stage renal disease itself was similar between groups, and serious adverse events were also similar. Even so, the higher rate of kidney-related events under more intensive treatment will shape how many clinicians think about the price of tighter blood pressure control in diabetes.
Kidney Signals Complicate the Case for a Universal Lower Target
The kidney findings are clinically important because pressure reduction can be both protective and destabilizing in diabetic kidney disease. Lowering systemic pressure can reduce glomerular stress over time, but aggressive treatment can also reduce renal perfusion, especially in patients whose kidneys already operate close to the edge of autoregulatory reserve. The observed imbalance in kidney-related events suggests that the physiologic tradeoff is not theoretical. It is embedded in the treatment strategy itself.
Otavio Berwanger, chair of the OPTIMAL-DIABETES Steering Committee, said the results should not be read as proof that intensive lowering has no value in Type 2 diabetes. A modest cardiovascular benefit may still exist, but it may be smaller than what has been seen in people without diabetes. A smaller effect size makes it harder for even a large trial to show a definitive difference, particularly when event rates are lower than expected or the follow-up period is finite.
The implication is a narrower one: blood pressure management in diabetes should remain individualized rather than forced into a single universal number. A target below 120 mm Hg may suit some patients, especially those with very high cardiovascular risk and good treatment tolerance. Others may pay more in medication burden, renal effects, or adverse physiologic stress than they gain in event reduction. In diabetes, the best target is often the one a patient can reach safely and sustain.
Why the Result Fits the Biology of Diabetes and Vascular Disease
Diabetes changes the vascular response to blood pressure in ways that can blunt the expected payoff from aggressive lowering. Atherosclerosis in this setting is often diffuse, microvascular dysfunction is common, and the kidneys may already be vulnerable from long-standing metabolic injury. Even when systolic pressure drops, residual risk can remain high because the disease process is not driven by pressure alone. Lipids, glycemia, inflammation, renal injury, and endothelial dysfunction continue to shape outcomes.
The average baseline systolic pressure was 146 mm Hg, with diastolic pressure at 80 mm Hg. After randomization, the treatment gap was meaningful, yet the outcome gap remained modest. That pattern suggests either that the benefit of very intensive control is limited in this population or that any benefit is small enough to require even larger or longer studies to detect with confidence. Either way, the data argue against automatic intensification for every patient with diabetes and elevated blood pressure.
Open-Label Design and Brazil-Only Enrollment Limit the Reach of the Findings
The main limitation is the open-label design. Participants and investigators knew which blood pressure strategy was being used, which can influence treatment decisions, adherence, and event ascertainment. The results also come from Brazil alone, so generalizability to other populations, health systems, and medication-use patterns is uncertain.
The trial enrolled from August 2019 to October 2021 and followed patients for four years. Those dates matter because contemporary diabetes and hypertension care already includes more sophisticated background therapy than older blood pressure trials. In that setting, detecting a further gain from lower systolic targets may be more difficult than it once was.
OPTIMAL-DIABETES adds a substantial new data set to a long-running question in cardiovascular prevention: how low should blood pressure go in adults with Type 2 diabetes? The answer emerging from this study is not a simple endorsement of intensive lowering and not a rejection of it either. It is a warning against reflexive treatment rules when vascular benefit, renal effects, and patient tolerance are pulling in different directions.